Regulatory Roundup: FDA Holds Special Press Briefing Regarding Revocation of Genentech's Avastin

Nov 23, 2011
By Pharmaceutical Technology Editors

FDA Commissioner Margaret Hamburg held a special press briefing last week on Genentech’s Avastin drug and its indications for metastatic breast cancer. She announced that the agency is revoking that indication based on FDA follow-up studies which did not show promising results. See related blog and press release.

lorem ipsum